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Abstract. Polymer-drug conjugates have gained signiﬁcant attention as pro-drugs releasing an active
substance as a result of enzymatic hydrolysis in physiological environment. In this study, a conjugate of 3-
hydroxybutyric acid oligomers with a carboxylic acid group-bearing model drug (ibuprofen) was
evaluated in vivo as a potential pro-drug for parenteral administration. Two different formulations, an
oily solution and an o/w emulsion were prepared and administered intramuscularly (IM) to rabbits in a
dose corresponding to 40 mg of ibuprofen/kilogramme. The concentration of ibuprofen in blood plasma
was analysed by HPLC, following solid–phase extraction and using indometacin as internal standard
(detection limit, 0.05 μg/ml). No signiﬁcant differences in the pharmacokinetic parameters (Cmax, Tmax,
AUC) were observed between the two tested formulations of the 3-hydroxybutyric acid conjugate. In
comparison to the non-conjugated drug in oily solution, the relative bioavailability of ibuprofen
conjugates from oily solution, and o/w emulsion was reduced to 17% and 10%, respectively. The 3-
hydroxybutyric acid formulations released the active substance over a signiﬁcantly extended period of
time with ibuprofen still being detectable 24 h post-injection, whereas the free compound was almost
completely eliminated as early as 6 h after administration. The conjugates remained in a muscle tissue for
a prolonged time and can hence be considered as sustained release systems for carboxylic acid
derivatives.
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Along with aqueous suspensions, oily solutions, micro-
spheres and implants, conjugates of drug substances with
biocompatible and biodegradable polymers have been
widely investigated for drug delivery applications (1,2). In
contrast to technologies based on drug incorporation into
the polymer matrix, conjugation to polymers signiﬁcantly
changes not only the pharmacokinetic properties of the
drug, but also its chemical and physicochemical character-
istics, including, e.g., solubility, stability and reactivity.
Some of these conjugates, mainly with polyethylene glycols
(PEG), have been approved and introduced into the clinic
as safe and effective alternative to the parent drugs (1).
Alternatives to PEG include polysaccharides (e.g.,d e x -
trans), vinyl polymers, poly amino acids and dendrimers
(3). Current research in the ﬁeld of biopolymers and
biomaterials is focused on the development of novel
polymers which are characterised by well-established
metabolism route, demonstrate absence of toxicity and
improve the pharmacokinetic properties of drugs, mainly
by extending their half-life time, enhancing their solubility,
reducing immunological reactions as well as fast elimina-
tion by enzymatic degradation (4).
A novel approach for drug conjugation are oligomers
of 3-hydroxybutyric acid (OHB) (5) which are synthesised
by a number of microorganisms and can also be found in
animal cells (6). Conjugates of carboxylic acid group-bearing
non-steroidal anti-inﬂammatory drugs (NSAIDs) with OHB
haverecentlybeendevelopedandcharacterisedattheCentre
of Polymer and Carbon Materials of Polish Academy of
Sciences. It was reported that these conjugates are biocom-
patible and show high stability in aqueous solutions of
pH 6.0–8.0 (7–9). Ibuprofen–OHB (Fig. 1) is a semi-solid
substance with good solubility in organic solvents including
oil (vegetable oils and Miglyol). It also marked resistance
against hydrolytic enzymes (e.g., pancreatin) (9), however, no
data on the conjugate's pharmacokinetics following paren-
teral administration has been available.
In the present study we discuss the in vivo pharmacoki-
netics of ibuprofen–OHB after IM injection into rabbits from
two different formulations, an oily solution and an o/w
emulsion. We also report on the development of a high
performance liquid chromatography (HPLC) method, pre-
ceded by SPE that was developed to analyse ibuprofen
concentrations in the collected plasma samples.
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Chemicals
Racemic ibuprofen (IB, Shasun, Chennai, India) was
kindly donated by Polfa Kutno (Kutno, Poland) and indome-
tacin (IND) was a gift from Jelfa (Jelenia Gora, Poland).
Ibuprofen–OHB (M.W. 570 Da) containing approximately
2.5% (w/w) of non-conjugated IB was provided by the Centre
of Polymer and Carbon Materials (Zabrze, Poland). Synthesis
and analytical methods conﬁrming purity, structure and
molecular weight of the conjugate have been described
elsewhere (9,10).
Acetonitrile (Merck, Darmstadt, Germany) and meth-
anol (POCh, Gliwice, Poland) were of HPLC grade.
Reagents for preparation of buffered solutions were also
purchased from POCh. For drug formulations, Miglyol 812
(medium-chain triglycerides, Caesar and Loretz, Hilden,
Germany), 86% (w/w) glycerol (Laboratorium Galenowe,
Olsztyn, Poland) and Tween 80 (Fluka, Buchs, Switzerland)
were used.
Instrumentation and Chromatographic Conditions
The HPLC system (Merck Hitachi, Darmstadt, Germany)
consistedof an isocraticHPLC pump (L-7100), autosampler(L-
7200), UV–vis detector (L-7420) and integrator (D-7000). As
stationary phase a LiChrospher 100 RP-18 column (5 μm,
Merck, Darmstadt, Germany) was used and the mobile phase
was a mixture of 10 mM phosphate buffer (pH 7.0) and
acetonitrile 70:30 (v/v). Flow rate was set to 1 ml/min, and
detection was performed at 220 nm.
Standard Solutions and Sample Preparation
For calibration, solutions of IB (5, 12.5, 25, 50, 125, 500
and 1,250 μg/ml) and a solution of an internal standard IND
(25 μg/ml) in methanol were used. Twenty microlitres of IB
solution and 20 μl of the internal standard solution were
added to 500 μl of blood plasma and vortexed for 10 s. Then,
100 μl of a 2% (w/w) solution of phosphoric acid and 600 μlo f
100 mM phosphate buffer (pH 6.0) were added, and the
sample was vortexed again for 30 s. SPE columns (Strata-X
33 μm, Phenomenex, Torrance, USA) were initially washed
with 1 ml of methanol followed by 1 ml of water according to
manufacturer's directions (11). The samples were applied to
the SPE columns and allowed to pass through without
vacuum being applied. The columns were then washed with
700 μlo f5 %( v/v) methanol in water. A vacuum was applied
for 1 min to remove residual solvents. The elution was carried
out using 1 ml of methanol. Collected solutions were
centrifuged (3,000×g) and 950 μl were transferred to HPLC
vials and the solvent was allowed to evaporate at 37°C under
a gentle stream of air. The residue was then dissolved in
200 μl of methanol, and 20 μl were injected into the HPLC
system.
Validation
Speciﬁcity of the method was determined at 220 nm by
comparing the chromatograms after extraction of blank plasma
and plasma spiked with IB (1 μg/ml) and IND (1 μg/ml).
Linearity was tested by extraction and injection of nine sets of
IB standard solutions in the concentration range 0.2–50 μg/ml.
Precision was calculated at different concentrations—0.2, 5 and
20 μg/ml. Repeatability and reproducibility were calculated
from the chromatograms of the same samples injected at
different time points during one day (n=3) or on three different
days, respectively. Accuracy was calculated by applying the test
procedure four times for three different IB concentrations (0.5,
2a n d5μg/ml). Recovery rates were determined by comparing
extractedspikedplasmasampleswithnon-extractedsolutionsof
standards in methanol (IB 1.25, 5 and 12.5 μg/ml). Limits of
detection and quantiﬁcation were also determined.
Drug Formulations
For parenteral administration of ibuprofen–OHB, a
25% (w/w) oily solution in Miglyol 812 and a 10% o/w
emulsion (20% of oily phase) were prepared. The oily
solution was obtained by dissolving ibuprofen–OHB in
Miglyol at 60°C, followed by sterilisation through ﬁltration
(0.2 μm cellulose acetate ﬁlters). The emulsion containing
ibuprofen–OHB, polysorbate 80 (2% w/w), glycerol (2.8%
w/w), Miglyol 812 and water was prepared by high-speed
homogenisation with an Ultra-Turrax T-25 (Janke and
Kunkel, Staufen, Germany). Sterilisation of the emulsion
formulation was performed by autoclaving (121°C, 15 min).
An oily solution of non-conjugated IB (5% w/w) in Miglyol
812 was prepared as control and also sterilised by ﬁltration
as described above. No adverse effects of the thermal
sterilisation on the emulsion stability were observed (9).
Parameters investigated were pH, droplet size and ibupro-
fen–OHB concentration. All formulations were prepared at
most 5 days prior to the start of the in vivo experiments,
however stability of the formulations at 5±2°C was
investigated within 90 days after preparation (9).
Pharmacokinetics of Ibuprofen after Ibuprofen-OHB
Administration in Rabbits
The animal experiments were designed to follow guide-
lines of the National Ethics Committee. The application was
reviewed and approved by the 4th Local Ethics Committee in
Warsaw (Permission N
o 25/2007). Eighteen adult rabbits (less
than 1 year old, nine males and nine females) with body
Fig. 1. Chemical structure of the conjugate of ibuprofen with
oligomers of 3-hydroxybutyric acid (n=3–7)
1637 In Vivo Assessment of Parenteral Formulationsweights of 2.73±0.32 kg were used. The animals were
purchased from Hodowla Krolikow Rasowych (Wielichowo,
Poland) and left to acclimatise for 1 week in the animal
facility, prior to the start of the study. The animals were fed
with standard rodent chow and had unrestricted access to
fresh water. The study was supervised and assisted by a
qualiﬁed veterinary surgeon and preceded accordingly to the
application approved.
The animals were divided into three groups of six (males
and females) and each group received one of the investigated
formulations by injection into the musculus semimembrano-
sus. Ibuprofen in oily solution was administered at doses of
25 mg/kg and ibuprofen–OHB in oil or in emulsion–at doses
of 120 mg/kg (corresponding to 40 mg/kg of IB). The total
injection volume, depending on the formulation, was between
1.1–3.5 ml. One-millilitre blood samples were collected in
heparinised plastic tubes (Medlab Products, Raszyn, Poland)
from the marginal ear vein prior to drug administration and at
1, 3, 6, 12, 24, 36, and 48 h after injection. Samples were
centrifuged at room temperature (15 min, 3,000×g) and the
plasma was separated and stored at −20°C until further
analysis. After addition of 20 μl of the internal standard
(IND, 25 μg/ml) to 500 μl of the plasma, samples were
acidiﬁed, diluted with 600 μl phosphate buffer (pH 6.0) and
analysed as described above.
Data Analysis
The calibration curves were calculated by linear regres-
sion of the IB/IND peak area ratio versus IB concentration.
The AUC0-24h (for IB formulation) or AUC0-48h (for ibupro-
fen-OHB formulations) was calculated using linear trapezoi-
dal rules. Statistical analysis was performed using Kruskal–
Wallis one-way analysis of variance. Individual differences
between the formulations were identiﬁed by Dunn's post hoc
test or by Mann–Whitney rank sum test. A signiﬁcance level
of p<0.05 denoted signiﬁcance in all cases.
Relative bioavailability (EBA) was calculated using
Eq. (1).
EBA ¼
AUCibuprofen OHB   DIB
AUCIB   Dibuprofen OHB
  100% ð1Þ
where AUC is area under curve and D is a dose of
ibuprofen–OHB or IB.
RESULTS
Analytical Method
The chromatographic conditions allowed for an evi-
dent separation of IB from the internal standard. Figure 2a
represents a sample chromatogram of plasma collected
during the experiment, spiked with IND and subjected to
SPE. Ibuprofen and IND are represented by peaks with
retention times at 4.5 and 6.3 min, respectively. Blank
plasma samples did not show any peaks with retention
times after 4 min (Fig. 2b). This suggests absence of
interferences of the analysed substances (IB and IND)
with endogenous compounds. A linear correlation between
IB/IND peak area ratio and IB concentration (CIB 0.2–
20 μg/ml) was clearly demonstrated (R
2=0.9999) and is
given by Eq. (2).
IB=IND ¼ 0:618   CIB þ 0:024 ð2Þ
The coefﬁcient of variation for the repeatability (within-
a-day) and the reproducibility (in-between-days) analyses was
2.06±3.18% and 10.05±7.03%, respectively. The percentage
of recovery from rabbit plasma was 75.5±8.3% for IB and
84.5±7.6% for IND. The method proved to be accurate, with
99.3±1.5% of IB detected in the analysed samples. The
quantiﬁcation and detection limits were 0.2 and 0.05 μg/ml,
respectively.
Drug Formulations
The properties and stability of ibuprofen–OHB drug
formulations as well as physicochemical characteristics of
the conjugate have been discussed elsewhere (9). Brieﬂy,
concentrations of ibuprofen-OHB, size of the emulsion
oily droplets as well as pH did not change signiﬁcantly
during the stability test (3% decrease in concentration
after 90 days was observed). On average, upper limit of
diameter for 50% of droplets (d0.5) was approximately
Fig. 2. Sample HLPC chromatogram of analysed plasma collected during the experiment, spiked with an
internal standard (IND, 2.5 μg/ml) and subjected to solid-phase extraction a and representative HPLC
chromatogram of extracted blank plasma sample b
1638 Stasiak et al.1.50 while the pH was 6.10. This did not change during
sterilisation process.
Pharmacokinetics of IB in Rabbits
The IB plasma concentrations after administration of
each formulation are shown in Table I and Fig. 3. Except
f o rt w oc a s e s( a n i m a l s2a n d8 ,T a b l eI), the maximum
concentration of IB in plasma was detected after approx-
imately 1 h, irrespective of the type of formulation.
Average IB Cmax values for ibuprofen–OHB preparations
were 1.3 and 1.0 μg/ml for the oily solution and emulsion,
respectively. However, this difference was not found to be
signiﬁcant (p<0.05). A higher concentration of IB in
plasma (Cmax 48.5 μg/ml) was found after injection of IB
compared with ibuprofen–OHB, despite administration of a
lower dose of IB (25 mg/kg versus 4 0m g / k gi nc a s eo f
ibuprofen-OHB). Six hours after injection, detectable IB
concentrations were only observable in plasma of three
rabbits receiving free IB; however, these samples were
below the limit of quantiﬁcation. In contrast, following
injection of ibuprofen–OHB formulations, detectable IB
plasma concentrations (up to 1 μg/ml) were found at the
time points up to 24 h. Four samples (Table I)w e r e
rejected from the analysis due to incoherence with the
expected pharmacokinetic proﬁle (rabbit 1; 24 h) or with
values measured at the same conditions for the other
animals from the same group (rabbit 7). It should be
Table I. Individual Plasma Concentration Proﬁles of IB Administered in a Form of Non-nonconjugated Substance and in a Form of the
Conjugate (Ibuprofen–OHB) as an Oily Solution and o/w Emulsion.
Animal N
o
Time (h)
AUC0-t (μg/ml·h) 13 6 1 2 2 4 3 6 4 8
Ibuprofen–OHB oily solution (40 mg IB/kg)
1 1.24 0.58 0.45 0.23 0.71
r 0.00 0.00
2 1.10 1.17 0.61 0.18
a 0.25 0.00 0.00
3 0.82 0.55 0.46 0.15
a 0.11
a 0.00 0.00
4 0.87 0.79 0.60 0.67 0.29 0.00 0.00
5 1,68 1.61 1.00 0.28 0.20 0.36 0.25
6 1.86 1.38 0.60 0.15
a 0.08
a 0.00 0.02
a
Mean±SD 1.26±0.42 1.01±0.44 0.62±0.20 0.28±0.20 0.19±0.09 0.06±0.14 0.04±0.1 13.2±6.7
Ibuprofen-OHB emulsion (40 mg IB/kg)
7 0.28
r 0.16
r 0.20
r 0.18
a 0.03
a 0.00 0.09
a
8 0.91 0.97 0.75 0.31 0.03
a 0.00 0.00
9 0.56 0.32 0.30 0.19
a 0.04
a 0.00 0.00
10 1.19 0.72 0.41 0.19
a 0.02
a 0.00 0.00
11 0.88 0.38 0.34 0.18
a 0.06
a 0.00 0.03
a
12 1.58 1.33 0.63 0.13
a 0.03
a 0.00 0.00
Mean±SD 1.02±0.38 0.74±0.42 0.49±0.19 0.20±0.06 0.04±0.01 0.00 0.02±0.04 7.9±2.2
IB oily solution (25 mg IB/kg)
13 37.36 2.07 0.01
a 0.00 0.01
a Not analysed
14 25,28 0.90 0.14
a 0.10
a 0.00
15 54,74 0.72 0.08
a 0.00 0.00
16 10.01 0.04
a 0.00 0.00 0.00
17 19.47 0.06
a 0.00 0.00 0.00
18 38.41 0.33 0.00 0.00 0.03
a
Mean±SD 30.88±15.91 0.69±0.76 0.04±0.06 0.02±0.04 0.01±0.01 48.4±25.1
aValues below quantiﬁcation limit
rData rejected
Fig. 3. Pharmacokinetic proﬁles of tested IM formulations: a Ibuprofen-OHB oily solution and
emulsion (40 mg IB/kg), b IB oily solution (25 mg/kg). Values are means of at least ﬁve independent
experiments (p*<0.05; Mann–Whitney rank sum test)
1639 In Vivo Assessment of Parenteral Formulationsstressed that the AUC values were calculated on a basis of
all obtained results, also these below LOQ, so they should
be treated rather as approximations (however, the preci-
sion calculated as a RSD between single injections did not
exceed 15% also for C values below 0.2 μg/ml). These
values were still reported (Table I) due to the fact that
their rejection did not signiﬁcantly change the ﬁnal AUC
(e.g. the values for ibuprofen-OHB emulsion were 7.9 and
7.15 μg/ml·h, respectively). Moreover, the precision was
assessed as sufﬁcient to demonstrate the time of drug
release.
Although the difference between AUCs obtained for
ibuprofen–OHB preparations (13.2 μg/ml·h for the oily
solution and 7.9 μg/ml·h for the emulsion) may indicate a
superior bioavailability of the pro-drug administered as an
oily solution, statistical analysis did not conﬁrm signiﬁcance
(p=0.129) between both preparations. Statistically signiﬁcant
difference, however, was shown 24 h after injection, when the
concentration of IB (0.19 μg/ml, with results below LOQ)
following administration of the oily solution of ibuprofen-
OHB was higher than after injection of the emulsion (all
results below LOQ).
A pronounced difference in bioavailability was demon-
strated between IB and ibuprofen–OHB preparations.
Despite a being nearly two times the lower dose of IB,
AUC values calculated for IB oily solution (48.4 μg/ml·h)
exceeded the AUC values for both ibuprofen–OHB prepa-
rations by four to six times. Consequently, the relative
bioavailability of IB bounded to OHB compared with the
IB preparation was relatively low (17.0% for the oily solution
and 10.0% for the emulsion).
DISCUSSION
A HPLC method was developed for the analysis of IB in
rabbit plasma which proved to be reliable, precise and
accurate. An internal standard (IND) chosen on a basis of
previous ﬁndings (12) allowed for appropriate peak separa-
tion. Although some authors obtained better validation
parameters, especially, with regards to the recovery of the
analysed substance (13,14), others reported values similar to
our ﬁndings (15).
An initial increase of IB plasma levels following ibupro-
fen-OHB administration with relatively early Tmax values
identical to the non-conjugated IB preparation can be
attributed to free IB present in the ibuprofen–OHB formu-
lation. Administration of 25 mg IB/kg as an oily solution
resulted in a Cmax of approx 30 μg/ml. Since the content of the
non-conjugated drug in ibuprofen–OHB was ~2.5% (9), the
animals receiving 120 mg/kg of ibuprofen–OHB (40 mg of
IB), received a dose of ~1.0 mg/kg of non-conjugated drug.
Hence, the expected Cmax of 1.2 μg/ml was conﬁrmed in the
experiment.
Hydrolytic breakdown of ibuprofen-OHB in vivo was
conﬁrmed by the presence of IB in the samples collected 6,
12 and 24 h after administration, while in rabbits receiving
free IB, the drug could no longer be detected. The very
slow rate of hydrolysis is also consistent with results
obtained previously in vitro, revealing after 72 h, only
15% of non-conjugated IB in pH 6.8 simulated intestinal
ﬂuid, and no signiﬁcant increase in IB concentration in
different phosphate-buffered solutions at a pH range 7.0–
8.0 (9). It can thus be deduced that, due to low hydrolytic
rate, almost all of the substance remains in the muscle
tissue.
Ibuprofen–OHB allowed for sustained release of the
active compound, although the slow hydrolysis of the
conjugate resulted in low plasma concentrations. This
phenomenon coincides with the published results of several
other groups (16,17) suggesting that the hydrolysis rate of
drug conjugates depends on the nature of chemical linkage
between the active molecule and the conjugated substance.
Faster hydrolysis rate would require incorporation of an
appropriate spacer group with hydrolytically unstable
bonds between the IB and OHB moieties, which has been
demonstrated to accelerate hydrolysis and allows for
detection of considerably higher drug levels in blood (17).
The observed hydrolysis proﬁle makes the oligo(3-hydrox-
ybutyric acid) conjugates particularly interesting for mono-
carboxylic acid drugs with considerable pharmacological
activity at low doses.
CONCLUSION
No signiﬁcant differences in pharmacokinetic charac-
teristics between ibuprofen–OHB emulsion and oily sol-
ution have been demonstrated. In comparison to non-
conjugated model drug, the conjugated form allowed for
prolonged release of the active substance. It can be
concluded that, due to reported lack of toxicity (5)a n d
sustained release characteristics, drug conjugates with oligo
(3-hydroxybutyric acid) are promising candidates for
parenteral drug carriers.
ACKNOWLEDGEMENTS
This work was supported by a Galenos Fellowship in the
Framework of the EU Project “Towards a European PhD in
Advanced Drug Delivery”, Marie Curie Contract MEST-CT-
2004-4049922. The authors wish to thank Ms. Anna Kowalc-
zyk and Ms. Iwona Kalinowska for their excellent technical
assistance during the experiments.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
REFERENCES
1. Pasut G, Veronese FM. Polymer-drug conjugation, recent
achievements and general strategies. Prog Polym Sci. 2007;32:933–
61.
2. Hamidi M, Azadi A, Raﬁei P. Pharmacokinetic consequences of
pegylation. Drug Deliv. 2006;13:399–409.
3. Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer–drug
conjugates: towards a novel approach for the treatment of
endrocine-related cancer. Endocr Relat Cancer. 2005;12:189–
99.
1640 Stasiak et al.4. Khandare J, Minko T. Polymer-drug conjugates: progress in
polymeric prodrugs. Prog Polym Sci. 2006;31:359–97.
5. Piddubnyak V, Kurcok P, Matuszowicz A, Glowala M, Fiszer-
Kierzkowska A, Jedlinski Z, et al. Oligo-3-hydroxybutyrates as
potential carriers for drug delivery. Biomaterials. 2004;25:5271–9.
6. Zinn M, Witholt B, Egli T. Occurrence, synthesis and medical
application of bacterial polyhydroxyalkanoate. Adv Drug Deliv
Rev. 2001;53:5–21.
7. Jedlinski Z, Juzwa M, Zawidlak-Wegrzynska B, Kaczmarczyk B,
Bosek I, Wanic A. Novel esters of nonsteroidal anti-inﬂamma-
tory drugs and methods of their preparation. Polish Patent PL
196384, 2007.
8. Juzwa M, Rusin A, Zawidlak-Wegrzynska B, Krawczyk Z,
Obara I, Jedlinski Z. Oligo(3-hydroxybutanoate) conjugates
with acetylsalicylic acid and their antitumour activity. Eur J
Med Chem. 2008;43:1785–90.
9. Stasiak P, Ehrhardt C, Juzwa M, Sznitowska M. Characterisation
of a novel conjugate of ibuprofen with 3-hydroxybutyric acid
oligomers. J Pharm Pharmacol. 2009;61:1119–24.
10. Zawidlak-Wegrzynska B, Kawalec M, Bosek I, Luczyk-Juzwa M,
Adamus G, Rusin A, et al. Synthesis and antiproliferative
properties of ibuprofen–oligo(3-hydroxybutyrate) conjugates.
Eur J Med Chem. 2010;45:1833–42.
11. http://www.phenomenex.com/AppManager/Files/CN-
007_Extraction%20of%20Ibuprofen%20from%20Plasma%
20using%20strata-X.pdf. Accessed 13 August 2009.
12. Sochor J, Klimes J, Sedlacek J, Zahradnícek M. Determina-
tion of ibuprofen in erythrocytes and plasma by high perform-
ance liquid chromatography. J Pharm Biomed Anal.
1995;13:899–903.
13. Farrar H, Letzig L, Gill M. Validation of a liquid chromato-
graphic method for the determination of ibuprofen in human
plasma. J Chromatogr B. 2002;780:341–8.
14. Bonato PS, Del Lama MP, de Carvalho R. Enantioselective
determination of ibuprofen in plasma by high-performance liquid
chromatography–electrospray mass spectrometry. J Chromatogr
B. 2003;796:413–20.
15. Gallardo A, Parejo C, San Roman J. NSAIDs bound to
methacrylic carriers: microstructural characterization and in vitro
release analysis. J Control Release. 2001;71:127–40.
16. Zhao X, Tao X, Wei D, Song Q. Pharmacological activity and
hydrolysis behavior of novel ibuprofen glucopyranoside conju-
gates. Eur J Med Chem. 2006;41:1352–8.
17. Babazadeh M. Synthesis and study of controlled release of
ibuprofen from the new acrylic type polymers. Int J Pharm.
2006;316:68–73.
1641 In Vivo Assessment of Parenteral Formulations